Prevention and Management of Graft-versus-host Disease. Practical Recommendations

Overview

Journal Drugs

Specialty Pharmacology

Date 1993 May 1

PMID 7686462

Authors

G B Vogelsang

L E Morris

Affiliations

Soon will be listed here.

Abstract

Graft-versus-host disease (GVHD) is the leading cause of failure of allogeneic bone marrow transplantation. The disease typically involves the skin, liver and gastrointestinal tract, with death frequently resulting from infectious complications. Cyclosporin-based drug combinations are the mainstay of GVHD prophylaxis. The major toxicity of cyclosporin is renal dysfunction, and optimal strategies of therapeutic drug monitoring to minimise toxicity and maximise clinical efficacy have yet to be devised. Initial treatment of established GVHD usually includes high dose corticosteroids. Patients failing to respond to first line therapy have a poor prognosis. Investigational approaches to decreasing the mortality associated with GVHD include using monoclonal antibodies directed at specific T cell subsets, and T cell depletion of bone marrow grafts.

References

Thomas E, Storb R, Clift R, Fefer A, Johnson F, Neiman P . Bone-marrow transplantation (first of two parts). N Engl J Med. 1975; 292(16):832-43. DOI: 10.1056/NEJM197504172921605. View

Forman S, Blume K, Krance R, Miner P, Metter G, Hill L . A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc. 1987; 19(1 Pt 3):2605-7. View

Weiden P, Flournoy N, Thomas E, Prentice R, Fefer A, Buckner C . Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979; 300(19):1068-73. DOI: 10.1056/NEJM197905103001902. View

Gale R, BORTIN M, van Bekkum D, BIGGS J, Dicke K, Gluckman E . Risk factors for acute graft-versus-host disease. Br J Haematol. 1987; 67(4):397-406. DOI: 10.1111/j.1365-2141.1987.tb06160.x. View

BORTIN M . Acute graft-versus-host disease following bone marrow transplantation in humans: prognostic factors. Advisory Committee of the International Bone Marrow Transplant Registry. Transplant Proc. 1987; 19(1 Pt 3):2655-7. View

Vogelsang G, Farmer E, Hess A, Altamonte V, Beschorner W, Jabs D . Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992; 326(16):1055-8. DOI: 10.1056/NEJM199204163261604. View

Billingham R . The biology of graft-versus-host reactions. Harvey Lect. 1966; 62:21-78. View

Steiner G, Kullinger B, Mayer G, Jie Y, Leibl H, Kovarik J . Determination of cyclosporine by a competitive binding assay with cyclophilin. Clin Chem. 1991; 37(3):403-10. View

Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico J . Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987; 2(8552):175-8. DOI: 10.1016/s0140-6736(87)90763-x. View

10.

Teraoka S, Takahashi K, Tanabe K, Yamaguchi Y, Kawai T, Tojinbara T . Improvement in renal blood flow and kidney function by modulation of prostaglandin metabolism in cyclosporine-treated animals. Transplant Proc. 1989; 21(1 Pt 1):937-40. View

11.

Paul K, Harding M, Marks W, Handschumacher R, Lorber M . Cyclophilin binding: a more accurate measure of cyclosporine immunosuppressive activity after renal transplantation. Transplant Proc. 1991; 23(1 Pt 2):974-5. View

12.

Deeg H, Storb R, Thomas E, Flournoy N, Kennedy M, Banaji M . Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood. 1985; 65(6):1325-34. View

13.

HIRVISALO E, Kivisto K, Neuvonen P . Therapeutic cyclosporine monitoring: comparison of radioimmunoassay and high-performance liquid chromatography methods in organ transplant recipients. Ther Drug Monit. 1990; 12(4):353-8. View

14.

Korngold R, Sprent J . Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978; 148(6):1687-98. PMC: 2185109. DOI: 10.1084/jem.148.6.1687. View

15.

Storb R, Deeg H, Thomas E, Appelbaum F, Buckner C, Cheever M . Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood. 1985; 66(3):698-702. View

16.

Holt D, Marsden J, Johnston A . Quality assessment of cyclosporine measurements: comparison of current methods. Transplant Proc. 1990; 22(3):1234-9. View

17.

Martin P, Schoch G, Fisher L, BYERS V, Appelbaum F, McDonald G . A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991; 77(8):1821-8. View

18.

Loo J, Gallicano K, McGilveray I, Beaudoin N, Jindal S . Monitoring of blood levels of cyclosporine in renal and cardiac transplant recipients--comparison of HPLC to Incstar CYCLO-Trac SP RIA. Clin Biochem. 1991; 24(1):49-53. DOI: 10.1016/0009-9120(91)90189-l. View

19.

Kivisto K . A review of assay methods for cyclosporin. Clinical implications. Clin Pharmacokinet. 1992; 23(3):173-90. DOI: 10.2165/00003088-199223030-00002. View

20.

Mitsuyasu R, Champlin R, Gale R, Ho W, Lenarsky C, Winston D . Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med. 1986; 105(1):20-6. DOI: 10.7326/0003-4819-105-1-20. View